Evaluation of efficacy and toxicity of nivolumab combined with or without docetaxel in patients with advanced NSCLC.

Yang WangJun NieLing DaiWeiheng HuJie ZhangXiaoling ChenXiangjuan MaGuangming TianJindi HanSen HanDi WuJieran LongZiran ZhangJian Fang

Published in: Cancer immunology, immunotherapy : CII (2021)

The combination of nivolumab and docetaxel demonstrated a meaningful improvement in progression-free survival and overall survival compared to nivolumab monotherapy, in patients with NSCLC after the failure of platinum doublet chemotherapy, irrespective of EGFR/ALK variation status.

Keyphrases

free survival
small cell lung cancer
advanced non small cell lung cancer
locally advanced
epidermal growth factor receptor
brain metastases
oxidative stress
tyrosine kinase
squamous cell carcinoma
combination therapy
randomized controlled trial
radiation therapy